|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Santhera Pharmaceuticals (USA), Inc.
| | | Phone: | (781) 365-0301 | Fax: | (781) 365-0230 | Year Established: | 2004 | Ticker: | SANN | Exchange: | SIX | Main Contact: | Thomas Meier, PhD, CEO | | Other Contacts: | Todd Bazemore, COO Kristina Sjöblom Nygren, CMO Giovanni Stropoli, CCO Günther Metz, Head Business Development Oliver Strub, General Counsel Christoph Rentsch, CFO
| | Company Description | Santhera Pharmaceuticals is a Switzerland-based specialty pharmaceutical company focused on the development and commercialization of small-molecule pharmaceutical products for the treatment of severe neuromuscular diseases, an area of high unmet medical need which includes many orphan indications with no current therapy. Santhera's first product, Catena® to treat Friedreich's Ataxia, is marketed in Canada. Data of a second pivotal Phase III study are expected for the first half of 2010. The drug has also shown efficacy in a clinical trial as a potential treatment for Duchenne Muscular Dystrophy. Recently reported results from a clinical trial demonstrate efficacy of JP-1730/fipamezole in reducing levodopa-induced Dyskinesia in Parkinson's Disease. The development portfolio consitsts of additional clinical programs, and will be grown further through in-licensing and reprofiling of existing compounds, driven by Santhera's in-house expertise in pharmacology. | |
|
|
|
|
|